Mecasermin

Mecasermin
Clinical data
Routes of; administration	Subcutaneous
ATC code	H01AC03 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
UNII	7GR9I2683O;
ChEMBL	ChEMBL1201716 ;
	(what is this?) (verify)

Mecasermin (INN, brand name Increlex) is recombinant human insulin-like growth factor 1 (IGF-I) which is used for the long-term treatment of growth failure in children with severe primary IGF-I deficiency.^[1]^[2]

This drug is not to be confused with mecasermin rinfabate (trade name: Iplex), which is the binary complex of recombinant human IGF-1 (rhIGF-1) and the binding protein that IGF-1 is naturally adhered to in the human body.

References

^ Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management. 5 (3): 553–9. PMC 2724186. PMID 19707272.
^ "Increlex". Drugs.com. Retrieved 10 January 2010.

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.

[1] Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management. 5 (3): 553–9. PMC 2724186. PMID 19707272.

[2] "Increlex". Drugs.com. Retrieved 10 January 2010.

[1]

[2]